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Abstract
Foxp3+ regulatory T (Treg) cells are essential for the maintenance of immune homeostasis and tolerance. During viral
infections, Treg cells can limit the immunopathology resulting from excessive inflammation, yet potentially inhibit effective
antiviral T cell responses and promote virus persistence. We report here that the fast-replicating LCMV strain Docile triggers
a massive expansion of the Treg population that directly correlates with the size of the virus inoculum and its tendency to
establish a chronic, persistent infection. This Treg cell proliferation was greatly enhanced in IL-21R2/2 mice and depletion of
Treg cells partially rescued defective CD8+ T cell cytokine responses and improved viral clearance in some but not all organs.
Notably, IL-21 inhibited Treg cell expansion in a cell intrinsic manner. Moreover, experimental augmentation of Treg cells
driven by injection of IL-2/anti-IL-2 immune complexes drastically impaired the functionality of the antiviral T cell response
and impeded virus clearance. As a consequence, mice became highly susceptible to chronic infection following exposure to
low virus doses. These findings reveal virus-driven Treg cell proliferation as potential evasion strategy that facilitates T cell
exhaustion and virus persistence. Furthermore, they suggest that besides its primary function as a direct survival signal for
antiviral CD8+ T cells during chronic infections, IL-21 may also indirectly promote CD8+ T cell poly-functionality by restricting
the suppressive activity of infection-induced Treg cells.
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Introduction
The immune system has to efficiently eliminate pathogens but
simultaneously needs to avoid the potential self-damage and
immunopathology caused by excessive immune activation.
Therefore, a tight regulation of immune responses is critical for
host survival. The subset of CD4+CD25+ regulatory T (Treg) cells
exerts key negative regulatory mechanisms of the immune system
that prevent autoimmunity and T cell mediated inflammatory
disease [1]. Treg cells are best defined by expression of the
signature transcription factor forkhead box P3, Foxp3
[2,3,4,5,6,7]. Their fundamental role in the maintenance of
immune homeostasis and tolerance is well established [8,9,10] and
unambiguously demonstrated by the severe multi-organ autoim-
mune disease, allergy and inflammatory bowel disease that
develops in Foxp3-deficient mice or patients with immune
dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX)
syndrome [3,11,12,13]. However, the relevance of Treg cell
responses for shaping adaptive immunity against pathogens, in
particular in the context of chronic infections, refigmains much
less understood.
Treg cells potentially have both beneficial and adverse effects on
disease outcomes during viral infections. By dampening effector
immune responses, Treg cell responses mitigate immunopathology
resulting from exaggerated inflammation and tissue destruction
during acute [14,15,16,17], or protracted infections
[18,19,20,21,22]. In addition, Treg cells have been shown to
support antiviral immunity by modulating T cell migration to the
site of infection [15,23]. Conversely, Treg cells were shown to
suppress CD8+ T cell responses in some infections [21,24], which
may prevent immunopathology, but hampers effective pathogen
control and ultimately promotes persistent infection [18,21,25,26].
Thus, while Treg cells favorably influence pathogen clearance in
many acute infections [14,15,16,23], they seem to negatively
regulate CD8+ T cell responses during chronic infections
[18,19,20,24,26]. Furthermore, elevated numbers of Treg cells
have also been associated with persistent viral infections in humans
[27,28,29]. However, to date little is known as to whether Treg cell
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activation represents a mechanism of immune evasion that
facilitates persistence, or about host factors that might regulate
Treg cell responses during chronic viral infection.
Many characteristics of persistent viral infections in humans,
such as HIV, HCV, or HBV, are also observed during chronic
infection of mice with the arenavirus lymphocytic choriomeningitis
virus (LCMV). Accordingly, murine models of chronic LCMV
infection have been extensively studied and have provided key
insights into the molecular mechanisms leading to virus persistence
and the associated modulation of adaptive immunity in face of
persistent infection. For example, infection with a high dose of the
fast-replicating strain LCMV Docile (or Armstrong clone 13)
results in virus persistence that is accompanied by a progressive
functional impairment and – for some specificities – even leads to
deletion of the virus-specific CD8+ T cell response, termed T cell
‘‘exhaustion’’ [30]. Exhausted antiviral T cells gradually lose their
capacity to produce antiviral cytokines and to proliferate ex vivo
[31,32,33]. Similar states of T cell exhaustion have been
demonstrated in patients with chronic HIV or HCV infections
[34]. CD8+ T cell exhaustion directly correlates with the antigen
load, i.e. is enhanced during prolonged or high viral replication.
Furthermore, CD8+ T cell exhaustion is also influenced by the
sustained expression of several inhibitory receptors [35] and
immunomodulatory cytokines, such as IL-10 [36,37] and TGFb
[38]. Moreover, it can be aggravated by the loss of help or essential
cytokines provided by CD4+ T cells. In particular, we and others
[39,40,41] have recently identified the pro-inflammatory cytokine
IL-21 as an essential CD4+ T cell-produced factor that prevents
CD8+ T cell exhaustion during chronic viral infection.
Here we have investigated the role of Treg cell responses in
chronic LCMV infection and found that the persistence-prone
strain Docile (DOC) induces a substantial dose-dependent
expansion of the Treg cell population that directly correlated
with the magnitude of the virus inoculum. The expanded Treg cell
population massively impaired the functionality of antiviral CD8+
T cells, interfered with virus clearance, and thereby promoted
chronic viral infection. Strikingly, enforced expansion of the Treg
cell population with IL-2/anti-IL-2 immune complexes (IL-2ic;
[42]) permitted the persistence of LCMV-DOC already at much
lower infection doses and even predisposed to chronic infection
with an LCMV-strain that generally fails to establish persistence in
immunocompetent mice. Importantly, this infection-triggered
expansion of the Treg cell population was greatly inhibited by
IL-21R signaling in Treg cells, thus defining a novel role for IL-21
in preventing T cell exhaustion and viral persistence via limiting
virus-driven Treg cell proliferation.
Results
Dose-dependent expansion of the Treg cell population in
response to chronic viral infection
We examined the role of Foxp3+ Treg cell responses in chronic
viral infections in mice infected with the fast-replicating strain of
LCMV-DOC. LCMV-DOC is characterized by its potential to
establish a chronic, persistent infection depending on the size of
the virus inoculum. Although low doses of LCMV-DOC (26102–
26103 PFU) induce potent CD8+ T cell-mediated immunity and
are cleared in immunocompetent hosts, infection with intermedi-
ate and high doses (26104–26106 PFU) results in virus persistence
due to the exhaustion of the virus-specific CD8+ T cell response
[30,31]. By choosing different virus inocula, we determined
dynamics of the Treg cell population during an acute, resolving
infection and a chronic infection. After an initial decline of Treg
cell numbers between days 0–7 that was independent of the dose
of infection and the LCMV strain used (i.e. DOC or WE)
(Figure 1A and data not shown), we observed a striking dose-
dependent expansion and recovery of the Treg cell population in
LCMV-DOC infected mice (Figure 1B, C) that directly correlated
with the ability of the virus to establish persistence (Figure 1D).
Compared to animals infected with a low dose of LCMV-DOC
(200 PFU), mice infected with intermediate (26104 PFU) or high
(26106 PFU) virus doses exhibited markedly increased propor-
tions of Treg cells in spleen and peripheral organs that amounted
up to 20% of all CD4+ T cells at 15 days post infection (Figure 1B,
C). At this time, infectious virus had been cleared from the blood
and organs of all mice infected with 200 PFU and some of the
animals infected with 26103 PFU of LCMV-DOC (Figure 1D
and data not shown); while mice infected with persistence-inducing
doses (26104–26106 PFU) of LCMV-DOC still exhibited high
viral titers in blood, spleen, liver and kidney, and subsequently
failed to control the infection (Figure 1D and data not shown). As
expected, we also detected a dose-dependent reduction in the
frequency of gp33-specific CD8+ T cells, which was indicative of
the progressing exhaustion of the T cell response, particularly in
the spleen (Figure 1E), and the resulting inability to resolve the
infection (Figure 1D).
Consumption and bioavailability of IL-2 by Treg cells has
been suggested to restrict IL-2-dependent effector T cell
differentiation and expansion [43,44,45,46]. Conversely, IL-
2-driven expansion of CD8+ T cell expansion during an
immune response can occur at the expense of Treg prolifer-
ation/survival [47,48]. Moreover, IL-21 has been suggested to
interfere with Treg-mediated suppression by inhibition of IL-2
[49]. To monitor IL-2 and IL-21 production during acute and
chronic infection, we took advantage of Il2-emGFP-Il21-
mCherry dual reporter transgenic mice [50] that were infected
with low dose (i.e. 200 PFU) LCMV-WE or high dose (i.e.
26105 PFU) LCMV-DOC. Both Il2 (GFP) and Il21 (mCherry)
were predominantly expressed by CD4+ compared to CD8+ T
cells and frequencies increased from days 7–15 post infection
with low dose LCMV-WE (Figure 1F–H). Interestingly,
chronic infection with high dose LCMV-DOC potently
Author Summary
T cell exhaustion represents a state of T cell dysfunction
associated with clinically relevant diseases, such as
persistent viral infections or cancer. Although the molec-
ular signature of exhausted T cells has been characterized
in detail at the functional and transcriptional level, the
immunological mechanisms that lead to T cell exhaustion
during chronic infections remain poorly understood. Our
present study reports two major findings that illustrate a
pathway that contributes to T cell exhaustion during viral
infection, and indicate its modulation by both, the
pathogen and the host. First, we show that a persis-
tence-inducing virus triggers the massive proliferation of
Foxp3+ regulatory T (Treg) cells and demonstrate the
potential of Treg cells to promote T cell exhaustion and
chronic infection. Second, we identify IL-21 as a crucial
host factor that antagonizes this virus-driven expansion of
the Treg population in a cell intrinsic manner independent
of IL-2. Thus, in addition to its known pre-dominant direct
positive effects on antiviral T cells, IL-21 can also alleviate
the suppressive activity of Treg cells. Together, these
results suggest enhanced Treg cell responses as a
mechanism of immune evasion that could be therapeuti-
cally targeted with IL-21.
IL-21 Antagonizes Tregs in Chronic Viral Infection
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suppressed Il2-GFP expression, but did not affect Il21-
mCherry expression by CD4+ T cells (Figure 1F–H).
Together, these data demonstrate a direct correlation between
the size of the virus inoculum, CD8+ T cell dysfunctionality, virus
persistence and the expansion of Treg cells, thus indicating a
potential contribution of Treg cells to the impaired T cell function
and the induction of viral persistence.
IL-21 antagonizes the virus-induced Treg cell expansion
during chronic infection
IL-21 receptor (IL-21R) signaling is essential for the mainte-
nance and sustained functionality of antiviral T cell responses in
chronic infections [39,40,41]. As a consequence, IL-21R2/2
animals have an impaired control of LCMV-DOC, and exhibit
much higher virus loads [40]. In LCMV-DOC infected WT mice,
the main Treg cell expansion was observed between days 10 to 20
post infection, peaking at 15 days before returning to almost naı¨ve
levels by five weeks post infection (Figure 2A, B). Strikingly, this
virus-driven Treg cell expansion was much more pronounced and
longer lasting in mice lacking IL-21R expression, which suggested
that the pro-inflammatory cytokine IL-21 restricted the prolifer-
ation of Treg cells in viral infections (Figure 2A, B). Indeed, the
Treg cells of naı¨ve and LCMV-DOC infected WT mice expressed
the IL-21R as assessed by flow cytometry (Figure 2C). We thus
investigated whether the increased Treg expansion observed in IL-
21R2/2 mice represented a direct inhibitory effect of IL-21 on
Treg cells or rather was related to the increased viral replication in
these mice. To address this issue, we generated mixed bone
marrow (BM) chimeras by reconstituting lethally irradiated WT
(CD45.1+) mice with a 1:1 ratio of WT (CD45.1+) and IL-21R2/2
(CD45.2+) BM, and evaluated their Treg cell responses to infection
with LCMV-DOC. Analysis of naı¨ve BM chimeras confirmed
similar reconstitution efficacy of the CD8+ and CD4+ T cell
populations including Treg cells from both WT and IL-21R2/2
donor BMs at 8 weeks after BM transfer (Figure 2D, and data not
shown). However, upon infection the population of IL-21R2/2
Treg cells expanded 3-fold over that of WT Treg cells to represent
30% versus 10% of all CD4+ T cells, respectively (Figure 2E–G).
Since this augmented proliferation of IL-21R2/2 Treg cells was
detected side by side to WT Treg cells in the same animals and
identical viral loads, it clearly established the direct inhibitory
effect of IL-21 on Treg cells in vivo. Nevertheless, we considered
that the higher Treg cell numbers in infected IL-21R2/2 mice
could not only result from the absence of inhibitory IL-21R
signaling but might also indicate a compensatory proliferation to
overcome a potential functional deficit of the IL-21R2/2 Treg
cells. To exclude the latter possibility, we isolated CD4+CD25+
GFP+ Treg cells from WT DEREG and IL-21R2/2 DEREG
mice by FACS-sorting 15 days post infection with 26106 PFU
LCMV-DOC, and compared their suppressive activity in a
classical T cell inhibition assay. As shown in Figure 2H, both
WT and IL-21R2/2 Treg cells comparably inhibited the
proliferation of anti-CD3/CD28–stimulated naı¨ve CD25negCD4+
T cells in vitro, suggesting a normal function of IL-21R2/2 Treg
cells. Thus, the increased expansion of IL-21R2/2 Treg cells in
LCMV-DOC infected mice highlighted an important inhibitory
role of IL-21 in restraining Treg cell expansion during chronic
LCMV infection. Except for a slightly reduced CD25 expression,
IL-21R2/2 Treg cells were comparable to WT Treg cells with
respect to the expression or characteristic Treg cell surface
markers (Figure 2I). We did not detect any IL-10 producing or
gp61-specific Treg cells in infected mice, suggesting that the
suppressive activity of Treg cells in LCMV-DOC infection
involved neither IL-10–mediated suppression nor virus-specific
Treg cells (Figure 2J and data not shown).
IL-6 has been suggested to regulate the balance between Treg
and pro-inflammatory Th17 cell responses [51,52] similar to IL-21
[53]. While we have previously shown that IL-17–producing
CD4+ T (Th17) cells were barely detectable in LCMV-DOC
infection [40], it remains possible that IL-21 inhibits Treg cell
expansion by regulation of IL-6. However, comparing IL-62/2
and WT mice we found no differences in Treg cell expansion
(Figure 2K), antiviral CD8+ and CD4+ T cell responses (Figure 2L,
M), and virus titers (Figure 2N) up to day 30 post infection with
26104 PFU LCMV-DOC. Together with the Treg cell-intrinsic
negative IL-21R2/2 signaling observed in WT:IL-21R2/2 mixed
BM chimeras, these data suggest that IL-21 restricted the virus-
driven Treg cell expansion in LCMV-DOC infection indepen-
dently of IL-6 signaling.
Depletion of Treg cells partially restores CD8+ T cell
functionality and increases disease severity during
chronic viral infection
To directly evaluate the impact of Treg cells on viral
persistence, we next sought to analyze antiviral T cell responses
and viral clearance in the absence of Treg cells. We therefore
studied LCMV-DOC infection using the DEREG mouse model,
in which Treg cells can be ablated by diphtheria toxin (DT)
treatment due to transgenic expression of a high affinity DT
receptor under control of the Foxp3 promoter [54]. DEREG and
nontransgenic WT control mice were treated with DT and
infected with 26105 PFU LCMV-DOC on day 0, and the DT
treatment was continued throughout the experiment (Figure 3A).
Since a single DT injection depleted Treg cells in naı¨ve mice for 3
days, we injected DT every 3 days to achieve complete Treg cell
ablation. While this treatment effectively depleted all Foxp3+ Treg
cells in naı¨ve DEREG mice ([54], and data not shown), we
consistently observed in LCMV-DOC infected DEREG mice the
emergence of a residual GFPnegFoxp3+ Treg cell population not
depleted by DT, presumably due to lacking expression of the GFP-
DTR fusion protein (Figure 3B). Compared to DT-treated WT
controls, Treg cell-depleted DEREG mice exhibited a greatly
enhanced morbidity in response to high dose LCMV-DOC
infection, as indicated by an increased weight loss (Figure 3C). As a
Figure 1. Virus dose-dependent expansion of the Treg cell population in response to chronic viral infection. Characterization of the
Foxp3+ Treg cell population in spleen (A–C), liver and kidney (B) of C57BL/6 WT mice at days 0 and 7 (A) and at day 15 (B, C) post infection with
indicated doses of LCMV-DOC. (A, B) Bar graphs show the mean6SEM of groups (n = 4–9) of mice. (C) Dot plots gated on CD4+ T cells from spleens of
individual mice representative for the group. (D) Viral titer in organs of individual mice as determined by plaque forming assay. Dotted horizontal
lines indicate the detection limit (DTL). (E) Percentage of gp33-specific CD8+ T cells in spleen, liver and kidney at 15 days post infection (dpi). Pooled
data from 2–4 independent experiments are shown. Data represent the mean 6SEM of 4–9 mice/group and was compared to mice infected with
200 PFU LCMV-DOC by one-way ANOVA using the Bonferroni correction. (F–H) Il2-emGFP-Il21-mCherry dual reporter transgenic mice were infected
with low dose (i.e. 200 PFU) LCMV-WE or high dose (i.e. 26105 PFU) LCMV-DOC. (F) Dot plots show IL-2-(emGFP) and IL-21 (mCherry) expression of
CD4+ T cells in blood of naı¨ve and day 8 LCMV infected mice without or with gp61 restimulation. (G–H) Shown are frequencies of (G) IL-2- or (H) IL-21-
expressing CD4+ and CD8+ T cells without (w/o) or with gp61 or gp33 peptide restimulation at days indicated. Values indicate averages of groups
(n = 2–3/group).
doi:10.1371/journal.ppat.1003362.g001
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result, a significant number of DT-treated, LCMV-DOC–infected
DEREG mice had to be prematurely removed from the
experiment and euthanized, whereas no equivalent morbidity
was observed in DT-treated WT mice (Figure 3D). Thus, Treg cell
depletion – even if not absolute – substantially aggravated the
disease severity in LCMV-DOC–infected DEREG mice. Deple-
tion of Treg cells did not affect the numbers of virus-specific CD8+
T cells, as indicated by the percentage of gp33-specific CD8+ T
cells in spleens and livers (Figure 3E). However, Treg cell-
depletion to some extent restored the functionality of the antiviral
CTL and significantly increased the frequencies of gp33-specific
and overall splenic CD8+ T cells producing IFN-c upon
restimulation in vitro (Figure 3F). In comparison, Treg cell-
depletion did not enhance frequencies of IFN-c–producing virus-
specific CD4+ T cells (Figure 3G). In spite of partly restoring CD8+
T cell cytokine responses, Treg cell depletion did not influence
virus control, and LCMV-DOC replicated to comparably high
levels in the blood and organs of DT-treated WT and DEREG
mice at 15 days post infection (Figure 3H). Thus, Treg cells
appeared to inhibit the functionality rather than the expansion of
antiviral T cells. Consistent with the observed onset of immuno-
pathology, the effect of Treg cell depletion on the antiviral T cell
response was more pronounced at 10 days post infection
(Figure 3I–M). Depletion of Treg cells resulted in higher
percentages of gp33-specific CD8+ T cells (Figure 3J) and
increased percentages of cytokine-producing antiviral CD8+ and
CD4+ T cells (Figure 3K, L), yet did not affect viral titers
(Figure 3M).
We next assessed the impact of increased Treg cell numbers in
IL-21R2/2 mice and treated both IL-21R2/2 and WT mice with
DT between days 8 to 15 post infection with 2000 PFU LCMV-
DOC (Fig. 4A). Although Treg cells were considerably (but not
entirely) depleted, frequencies of gp33-specific CD8+ T cells
remained unchanged (Figure 4B, C) similar to the results obtained
by depletion through the entire course of infection (Figure 3B, E).
However, Treg cell depletion partially restored frequencies of IFN-
c-producing gp33-specific cells in IL-21R2/2 mice to levels found
in WT mice (Figure 4D). Furthermore, Treg cell depletion lowered
virus titers significantly in liver and lung of IL-21R2/2 mice,
although viral loads in spleen and kidney remained unaffected
(Figure 4F).
Whether the differences in antiviral CD8+ T cells were too
small to result in better virus control or whether the failure to
detect differences in viral titers (Figure 3H, M) has to be
attributed to the suppressive activity of the residual Treg cells
that resisted DT depletion (Figures 3B and 4B) remains to be
clarified. Regardless, our results establish a link between the
functional impairment of the CD8+ T cell response and the
elevated Treg cell levels observed during chronic infection in
absence of IL-21.
IL-2 driven Treg cell expansion inhibits antiviral T cell
responses and promotes persistent viral infection
We next examined the potential of Treg cells to limit the antiviral
immune response and to promote virus persistence in a gain of
function approach. For this purpose, we injected immune
complexes (ic) comprised of recombinant IL-2 and the anti-IL-2
antibody JES6-1 [42], to selectively expand the subset of
Foxp3+CD4+ Treg cells in vivo (Figure 5A). In naı¨ve mice, three
injections of IL-2ic drastically expanded the Treg population to
represent 40–50% of all CD4+ T cells in blood, spleen and liver
within 5 days after the first injection (Figure S1 and Figure 5B).
Similarly, IL-2ic treatment triggered a pronounced expansion of
Treg cells in mice infected with 26103 PFU LCMV-DOC,
established stably elevated levels of Treg cells in blood for at least
30 days (Figure 5B), and thus appeared comparable to that observed
during high dose LCMV-DOC infection. The Treg cell population
of infected, IL-2ic-treated mice was fully comparable to that of
untreated, infected mice, with respect to cell surface expression of
FR4, GITR, CD103 and CD25 (Figure 5C) as well as TCR–Vb
profiles (data not shown). The IL-2ic-stimulated expansion of the
Foxp3+ Treg cell population profoundly interfered with generation
and maintenance of gp33-specific CD8+ T cells, CD62L downreg-
ulation, and their capacity to produce IFN-c and TNF-a as
measured in spleen and liver at days 15, 30, and 65 post infection
(Figure 5D–G, and Figure S2), which is reminiscent of the state of
exhaustion that usually coincides with viral persistence in high dose
LCMV-DOC infection. Accordingly, this long lasting impairment
of antiviral T cells in presence of the enhanced Treg cell expansion
prevented IL-2ic–treated animals from controlling a low dose
LCMV-DOC infection. While infectious virus was readily cleared
from the blood and most organs in control mice within 15 days, IL-
2ic-induced Treg cell expansion resulted in a failure to clear virus in
spleens, livers, kidneys and lungs for more than 2 months
(Figure 5H–J). Notably, IL-2ic expanded Treg cells also impaired
antiviral CD8+ T cell effector responses and viral clearance of low
dose LCMV-WE infection, which is otherwise rapidly cleared
irrespectively of the viral inoculate (Figure S3).
Taken together, the experimental expansion of Treg cells
recapitulated both the long lasting functional impairment of the
antiviral T cell response and the viral persistence that characterize
high-dose LCMV-DOC infection in the setting of a low dose
inoculum, and thus emphasized the remarkable potency of Treg
cells to facilitate persistent viral infections. While Sprent and
colleagues have clearly shown that IL-2:IL-2mAb (JES6-1) primar-
ily target high affinity IL-2R+ Treg cells and have minimal effects on
low affinity IL-2R+ naı¨ve and memory CD8+ T cells [42], we cannot
completely rule out the possibility that the IL-2:IL-2mAb also target
high affinity antiviral effector CD8+ T cells resulting in terminal
differentiation and exhaustion. However, this scenario appears
Figure 2. IL-21 antagonizes virus-induced Treg cell expansion during chronic infection. (A) Frequencies of splenic Foxp3+CD25+CD4+ T
cells from WT and IL-21R2/2 mice at indicated days after infection with indicated doses of LCMV-DOC. (B) Total numbers of Foxp3+ cells (2000 PFU
LCMV-DOC, 15 dpi). (C) IL-21R expression on GFP+CD4+Treg cells of naı¨ve and LCMV-DOC infected DEREG mice (26104 PFU, 15 dpi). The mean
fluorescent intensity (MFI) of single mice (left panel) and averages 6 SEM of groups (n = 4) (right panel) are shown. (D–G) Analysis of WT (CD45.1+):IL-
21R2/2(CD45.2+) mixed BM chimeras. (D) Blood frequencies of CD4+, CD8+ and Foxp3+CD25+CD4+ T cell populations derived from WT and IL-21R2/2
BM 8 weeks after BM transfer prior LCMV infection. Reconstitution efficiency of WT and IL-21R2/2 lymphocytes (lym) were in average 51%:49% and
values for the CD4+ and CD8+ T cell populations were corrected for chimerism. (E) FACS plots show CD25 and Foxp3 expression of CD4+ T cells, (F)
graphs show frequencies and (G) total numbers of splenic Foxp3+CD25+ Treg cells 35 dpi with 2000 PFU LCMV-DOC. (H) Suppressive activity of FACS-
sorted CD4+CD25+ Treg cells from infected DEREG or DEREGxIL-21R2/2 mice was assessed as described in Materials and Methods. (I) Cell surface
expression of putative Treg markers and (J) IL-10 production by Foxp3+CD4+ T cells isolated from WT or IL-21R2/2 mice infected with 26104 PFU
LCMV-DOC 15 dpi. (J) Dot plots depict IL-10 production of splenic Foxp3+ T cells of WT or IL-21R2/2 mice after restimulation with gp61. Shown are
representative individuals of groups of mice (n = 4). (K–N) IL-62/2 and WT mice (n = 5/group) were infected with 26104 PFU LCMV-DOC and analyzed
30 dpi. Shown are frequencies of Foxp3+ cells (K), gp33-specific CD8+ T cells (L), IFN-c-producing CD8+ and CD4+ T cells (M), and virus titers in organs
indicated (N). (A–N) Data represent one of two independent experiments.
doi:10.1371/journal.ppat.1003362.g002
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Figure 3. Depletion of Treg cells partially restores CD8+ T cell functionality and increases disease severity. DEREG and C57BL/6 WT
mice were infected with 26105 PFU LCMV-DOC and treated with diphtheria toxin (DT) for depletion of Foxp3+ cells as illustrated in (A, I). (B) Dot plot
of GFP and Foxp3+ expressing cells gated on CD4+ T cells from naı¨ve and infected mice treated or untreated with DT. (C) Morbidity indicated by
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unlikely considering the time of treatment with the IL-2:IL-2mAb
complexes (i.e. days 0–2), their short half-life (i.e. 4 h) [42], and the
normal expansion of antiviral CD8+ T cells until day 7.
The above data demonstrate the differential regulation of the Treg
cell population during viral infection by IL-2 and IL-21. To better
understand counter-regulation of Treg cells by IL-2 and IL-21 in the
absence of confounding virus dynamics, we delivered the IL-21 gene by
hydrodynamic injection to IL-2ic treated mice in the absence of viral
infection (Figure 6). Indeed, IL-21 significantly inhibited IL-2ic driven
expansion of Treg cells. Similar results were obtained by co-injection of
an engineered IL-21-Fc fusion protein together with IL-2ic. Together,
these data indicate that IL-21 interferes with IL-2 driven expansion of
Treg cells to optimize antiviral effector T cell responses.
Discussion
T cell exhaustion represents a state of T cell dysfunction
associated with clinically relevant diseases, such as persistent viral
weight loss and (D) percentage of surviving mice for groups of 8 mice. (E) Expansion of virus-specific CD8+ T cells and cytokine production of splenic
(F) CD8+ and (G) CD4+ T cells as detected with gp33-specific tetramers or intracellular cytokine staining after restimulation with specific peptide or
PMA/Ionomycin. (H) Virus titers in blood (left panel) and organs (right panel) of individual mice at 15 dpi. Dotted lines indicate the detection limit
(DTL). (J) Percentages of gp33-specific CD8+ T cells in spleen, liver, and lungs 10 dpi. Frequencies of splenic IFN-c-producing CD8+ T cells (K) and CD4+
T cells (L) after restimulation with specific peptide (left graph) or PMA/Ionomycin (right graph). (M) Virus titers in blood and organs of individual mice
10 dpi. Dotted lines indicate the detection limit (DTL). Data are representative of two independent experiments including n = 8 (A–H) or n = 4 (I–H)
mice per group. Symbols depict individual mice and lines indicate averages of groups.
doi:10.1371/journal.ppat.1003362.g003
Figure 4. Depletion of Treg cells partially restores CD8+ T cell functionality in WT and IL-21R2/2mice. DEREG, C57BL/6 (WT), DEREGxIL-
21R2/2 and IL-21R2/2 mice were infected with 2000 PFU LCMV-DOC and treated with diphtheria toxin (DT) at indicated days before analysis at day
15 as illustrated in (A). (B) Percentages of Foxp3+ Treg cells and (C) gp33-specific CD8+ T cells in the spleen. (D, E) Frequency of IFN-c-producing CD8+
(D) and CD4+ (E) T cells as assessed by intracellular cytokine staining after in vitro restimulation with specific peptide or PMA/Ionomycin. (F) Shown are
virus titers in organs of individual mice 15 dpi. Dotted lines indicate the detection limit (DTL). Dots represent individual mice, the lines the averages
(*p#0.05).
doi:10.1371/journal.ppat.1003362.g004
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Figure 5. Forced Treg cell expansion inhibits antiviral T cell responses and interferes with effective virus clearance. (A) Mice were
infected with 2000 PFU LCMV-DOC and treated with IL-2/anti-IL-2mAb immune complexes (IL-2ic) or untreated (ctrl) as illustrated. (B) Frequencies of
Treg cells measured longitudinally in blood (left) and at 15 dpi in spleen and liver (right). (C) Cell surface expression of putative Treg markers on
Foxp3+CD4+ T cells of individuals out of a group (n = 4) of mice. (D) Percentages of gp33-specific CD8+ T cells in blood at days indicated. (E–G)
Frequency of IFN-c- and TNF-a-producing CD8+ and CD4+ T cells after in vitro restimulation with gp33 and gp61 peptides at day 15 (E–F) and day 65
(G) post infection (H–J). Values show virus titers in blood at days indicated (H) and in organs of individual mice at days 30 (I) and 65 (J) post infection.
Dotted lines indicate the detection limit (DTL). Data are representative of two (A–B) or three (C–I) independent experiments. Symbols represent
individual mice and lines averages of the groups.
doi:10.1371/journal.ppat.1003362.g005
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infections or cancer. Even though the molecular signature of
exhausted T cells has been characterized in detail at the functional
and transcriptional level [32,34], we are only beginning to
understand the immunological mechanisms that support or
counteract the development of T cell exhaustion during chronic
infections [35]. In this study we report two major findings that
establish a pathway of T cell exhaustion mediated by Treg cells
during viral infection, and indicate its modulation by both, the
pathogen and the host. First, we show that a persistence-inducing
virus triggers the massive proliferation of Treg cells between days
9–20 post infection and demonstrate the potential of Treg cells to
promote T cell exhaustion and chronic infection. Second, we
identify IL-21 as a crucial host factor that antagonizes this virus-
driven expansion of the Treg cell population. Together, these
results suggest enhanced Treg cell responses as a mechanism of
immune evasion that could be therapeutically targeted with IL-21.
Treg cells are essential for immune homeostasis and T cell
tolerance [8,9], yet their contribution to anti-infectious immune
responses is poorly defined. In the setting of persistent viral
infections that was investigated here, Treg cells appear to down-
regulate antiviral T cell responses, and thus prevent the potentially
lethal immunopathology caused by prolonged immune activation
in presence of highly replicating virus (Figure 3). Supporting this
notion, clinical studies have associated high numbers of Treg cells
to chronic infection with HIV [29], HCV [28,55], or HBV [56],
whereas low Treg cell numbers have been reported for elite HIV
controllers [57], which collectively suggests that Treg cells
modulate the equilibrium between host immune response and
persisting virus [27][34]. Our study has now recapitulated these
observations in a murine model of persistent viral infection and
applied experimental manipulation of the Treg cell response to
define the direct link between virus-induced Treg cell expansion
and T cell exhaustion. Our initial observation that titrated doses of
LCMV-DOC induce graded degrees of Treg cell proliferation and
T cell exhaustion allowed us to assess the impact of such virus-
induced Treg cell expansion under ‘‘non-persisting conditions’’
using the identical LCMV strain. Although the expansion of Treg
cells with IL-2ic achieved very high Treg cell numbers, it is
important to note that this level of Treg cell expansion was fully
comparable to that induced with LCMV-DOC at high doses or in
IL-21R2/2 mice. The Treg cell responses triggered by LCMV-
DOC in presence or absence of IL-2ic treatment did not
phenotypically differ with respect to their cell surface marker
expression and exhibited TCRb profiles similar to that described
for LCMV clone 13 infection [58]. Thus, the IL-2ic-elicited Treg
cell proliferation appeared to truly mimic the physiological Treg
cell expansion during chronic LCMV-DOC infection.
These experiments exposed two facets of the antiviral Treg cell
response in LCMV-DOC infected mice that are central for our
understanding of the role and potential of Treg cells within
antiviral and anti-tumoral responses. First, the increased morbidity
in Treg-depleted DEREG mice infected with LCMV-DOC
clearly revealed the critical role of Treg cells for preventing lethal
immunopathology caused by potent immune responses to
persisting antigen. Second, both the depletion as well as the gain
of function approach demonstrated that Treg cells primarily
modulate the functionality (e.g. cytokine response, antiviral
activity) of antiviral T cells rather than influencing their priming
consistent with an earlier report showing compromised cytolysis
but no defect in priming, proliferation and motility of regulated
CTLs [59]. This finding is especially promising, since it implies
that the primed but exhausted antiviral T cells present in
chronically infected subjects could be therapeutically rescued by
removal of Treg cell-mediated suppression.
Dynamics of regulatory and effector T cell populations in
homeostasis and during an immune response are very sensitive to
the availability of IL-2. Competition for IL-2 between effector and
regulatory T cells has been suggested to control tolerance and
immunity or the outcome of infectious disease. Associated with the
rapid expansion of virus-specific CD8+ T cells in the early phase of
infection between days 0 to 8, we observed a remarkable drop in
Treg cells below naı¨ve levels irrespective of the LCMV inocula
and strain used. This has also been observed in other infections
and suggested to be due to consumption of IL-2 by expanding
CD8+ T cells and required for efficient clearance of the invader
[47,48]. While this appears feasible, it should be noted that
expansion of CD8+ T cells in the acute phase of LCMV infection
is independent of IL-2 [60,61] and that hyper-proliferation of Treg
Figure 6. IL-21 delivery impairs IL-2ic driven expansion of Treg cells. Expression vectors encoding the IL-21 gene fused with the hIgG1 (IL-
21pDNA) or a control hIgG1 gene (ctrl pDNA) alone were delivered to C57BL/6 mice by hydrodynamic injection 24 h prior injection of IL-2ic.
Alternatively, IL-2ic treated C57BL/6 WT mice were injected with 2 mg of IL-21-hIgG1 fusion protein consecutively every 12 h from days 0–5. Foxp3+
Treg cells were measured (A) in the blood at days indicated and (B) in spleen and liver at day 6 by flow cytometry. (C) Marginal zone B cells in the
spleen at day 6. Values show percentages of Foxp3+ T cells of CD4+ T cells (A, B) and CD21+CD23low of CD19+ cells (C). Dots represent individual mice
and lines indicate averages (*p#0.05).
doi:10.1371/journal.ppat.1003362.g006
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cells between days 10–20 in chronic LCMV infection was
associated with potent suppression of IL-2 production by CD8+
T cells (Figure 1F, G) arguing that IL-2 availability does not
sufficiently explain cross-regulation of effector CD8+ T cells and
Treg cell proliferation in acute and chronic LCMV infection. In
vitro experiments suggested that IL-21 could inhibit Treg cells by
suppression of IL-2 production in CD4+ effector T cells [49].
However, our results in the WT:IL-21R2/2 mixed BM chimeric
mice demonstrate that IL-21 inhibits Treg cell expansion directly
in a cell intrinsic manner (Figure 2E–G). The finding that
expansion of Treg cells induced by IL-2ic treatment was impaired
by simultaneous (hydrodynamic) overexpression of the IL-21 gene
(Figure 6) further supports this conclusion. Thus, IL-2 and IL-21
exert opposing activities on Treg cells, while they cooperate in
driving effector and memory T cell responses, which adds another
level of complexity to theoretical and experimental models
addressing the dynamics of Treg cells and effector T cells [45].
Amongst the known Treg cell effector molecules, IL-10 has
been shown to support the functional impairment of T cell
responses during chronic infection with LCMV clone 13 [36,37].
However, we were unable to detect any IL-10-producing Treg
cells in LCMV-DOC infected mice (Figure 2J). Furthermore, IL-
10 blocking antibodies or genetic IL-10-deficiency did not prevent
T cell exhaustion and viral clearance in response to LCMV-DOC,
in contrast to LCMV clone 13 infection [62]. The exhausted T
cells in chronically LCMV infected mice have been shown to
upregulate expression of several co-inhibitory receptors, e.g. PD-1
and Tim3, which contribute to T cell exhaustion in the LCMV
model [63,64] and in human HIV patients [65,66]. It will thus be
important to test whether these pathways are involved in the Treg
cell-induced T cell exhaustion described in our study. Though a
detailed characterization is beyond the scope of the current
analysis, the experiments described in this manuscript will provide
the framework for further mechanistic studies.
IL-6 and IL-21 have similar activities and interact in the cross-
regulation of inducible Treg and Th17 cell development in vitro and in
vivo depending on the experimental model [51,52,53,67,68]. Interest-
ingly, while IL-6 has recently also been shown to be essential for viral
control by enhancing follicular T helper cell responses at late stages of
chronic infection [69], virus titers and Treg numbers were comparable
in LCMV-DOC infected IL-62/2 and WT mice up to day 30 post
infection (Figure 2K–N) [69]. Therefore, during chronic LCMV-DOC
infection, the inhibition of virus-induced Treg cell expansion is a
distinct function of IL-21, which is not accompanied by elevated IL-17
production of CD4+ T cells [40].
The importance of cell-intrinsic IL-21R signaling for the
maintenance of CD8+ T cell functionality has been well
documented [39,40,41] and is considered as the primary effect
of IL-21 promoting the immune control of chronic viral infections.
However, the present report clearly demonstrates that besides this
direct function on CD8+ T cells, IL-21 also efficiently restricts the
virus-induced expansion of the Treg population in a cell intrinsic
manner. It remains to be clarified to which extent the direct effects
of IL-21 on CD8+ T cells and its indirect effects on CD8+ T cells
via the inhibition of Treg cells differentially contribute to the
overall protective function of IL-21 in chronic viral infections
considering that we only achieved limited recovery of T cell
functionality (e.g. regain of cytokine production) and improved
viral clearance only in lung and liver but not spleen and kidney of
IL-21R2/2 mice by Treg depletion. It should be noted, however,
that, for reasons unknown, a fraction of (GFPnegFoxp3+) Treg cells
resisted depletion by diphtheria toxin during LCMV infection in
both IL-21R2/2 and WT mice, although Treg depletion in naive
mice was almost complete (.98%). It remains to be investigated
whether the undeletable GFPnegFoxp3+ cells can compensate for
the deleted Treg cells or represent a subpopulation of Treg cells
that is responsible for maintenance of regulatory activity in
LCMV-infected DEREG mice.
Regardless, our findings suggest a dual importance of IL-21 for
preventing T cell exhaustion during chronic viral infections, and
demonstrate that IL-21 in addition to its known direct effects on
antiviral T cells [39,40,41] also partially alleviates the suppressive
activity of Treg cells. Notably, in a model of acute lung infection, it was
recently demonstrated that IL-21R2/2 mice are protected from fatal
lung immunopathology induced by pneumonia virus [70]. It is
tempting to speculate that IL-21 might aggravate immunopathology
by suppression of Treg cells in this infection model.
In summary, our data support the concept of virus-induced
Treg cell expansion as an active immune evasion strategy, and
thus highlight a novel pathway by which viruses exploit regulatory
mechanisms of the immune system to establish persistent infection.
In view of the relevance to human disease these results have
direct therapeutic implications and suggest strategies that boost IL-
21 signaling in T cells as novel treatment options for chronic viral
infections and cancer.
Materials and Methods
Viruses and mice
The LCMV strains WE and DOC were originally provided by
Rolf Zinkernagel (University of Zurich, Switzerland) and were
propagated on L929 or MDCK cells, respectively. C57BL/6 WT
and IL-62/2 mice [71] were from Charles River Inc. SMARTA-2
mice (expressing a transgenic TCR specific for LCMV-GP 61–80;
[72] and IL-21R2/2 mice [73] were bred locally. DEREG-mice
[54] were kindly provided by Tim Sparwasser (TWINCORE,
Hannover, Germany) and crossed with the IL-21R2/2 strain at
our facility. Il21-mCherry/Il2-emGFP dual-reporter transgenic
mice [50] were kindly provided by Warren Leonard, National
Institutes of Health, Bethesda, MD, USA. Mice were housed in
individually ventilated cages under specific pathogen free condi-
tions at BioSupport AG (Zurich, Switzerland). For the generation
of BM chimeras, recipient mice were lethally irradiated (9.5 Gy,
using a cesium source) one day before reconstitution with 16107
CD4/CD8-depleted (Miltenyi Biotec) BM cells. Mice were
infected i.v. with the indicated virus doses.
Ethics statement: All animal experiments were approved by the
local animal ethics committee (Kantonales Veterina¨rsamt Zu¨rich,
licenses 217/2008 and 113/2012), and performed according to
local guidelines (TschV, Zurich) and the Swiss animal protection
law (TschG).
Cells and reagents
All cell lines were originally obtained from the American Tissue
Culture Collection (ATCC). Chemicals were purchased from Sigma-
Aldrich except were otherwise stated. PE- and APC-conjugated
peptide-MHC class I tetramers (H-2Db/gp33-41) were generated as
described [74] or kindly provided the NIH tetramer core facility. The
LCMV-GP peptides gp33-41 (KAVYNFATM) and gp61-80
(GLNGPDIYKGVYQFKSVEFD) were bought from Mimotopes.
The following antibodies (all eBioscience unless otherwise stated; clone
names given in parentheses) were used for flow cytometry: FITC-
labeled anti-CD4 (L3T4), anti-CD62L (MEL-14); PE-labeled anti-
CD4 (GK1.5; conjugated in our laboratory), anti-CD8a (53-6.7;
BioLegend), anti-CD25 (PC61), anti-GITR (DTA-1; BioLegend), anti-
CD103 (2E7), anti-FR4 (12A5; BioLegend), anti-IL21R-biotin (4A9) –
Streptavidin-RPE (BioLegend) and anti-TNF-a (MP6-XT22); PerCP-
labeled anti-CD4 (RM4-5; BioLegend), anti-CD45.1 (A20; BioLe-
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gend), anti-CD8 (53-6.7; BD); APC-labeled anti-CD4 (GK1.5), anti-
CD127 (SB/199; Biolegend), anti-CD8 (53-6.7; BioLegend), anti-
CD45.2 (104), anti-IL21R (4A9; BioLegend), anti-Foxp3 (FJK-16S),
anti-IFN-c (XMG1.2; BioLegend), anti-IL-2 (JES6-5H4), anti-IL-10
(JES5-16E3).
Manipulation of Treg cells
In depletion experiments, DEREG and WT control mice were
i.p. injected with DT (Merck) diluted in PBS. After an initial dose
of 200 ng DT, mice were treated with 100 ng DT every third day
unless otherwise indicated. To boost Treg cells, mice received 3
daily i.p. injections of IL-2ic generated from carrier-free recom-
binant mouse IL-2 and anti-IL-2 mAb (JES6-1A12; both from
eBioscience) as described [42].
Flow cytometry
Tetramer and antibody staining was performed on blood cells and
single cell suspensions prepared from organs. Spleens and kidneys were
passed through a 70 mM cell strainer to obtain single cell suspensions.
Livers were first dissected into small pieces, and then passed through a
cell strainer before lymphocytes were purified by Lympholyte M
gradient centrifugation (Cedarlane Laboratories Ltd.). Blood samples
were pretreated with red blood lysis buffer (155 mM NH4Cl, 10 mM
KHCO3, 0.1 mM EDTA, pH 7) for 10 min at RT. Cells were
incubated with anti-CD16/CD32 mAb (2.4G2) to block FccR. For
surface staining, cells were incubated at RT with peptide MHC I
tetramers in FACS buffer (FB; PBS containing 0.5% BSA) for 15 min
followed by addition of the relevant surface antibodies and incubation
for additional 20 min at 4uC. Cytokine-production by T cells was
assessed using intracellular cytokine staining of single cell suspensions
that had been stimulated in presence of 2 mg/ml Monensin with either
1 mM specific peptide or 100 ng/ml PMA and 1 mg/ml Ionomycin for
4 hours in vitro. The cells were surface-stained, fixed with 4%
Formaldehyde in PBS and permeabilized with permeabilization buffer
(FB containing 1% Saponin). Intracellular staining was then performed
in permeabilization buffer at 4uC for 20 minutes. After 2 washes with
permeabilization buffer, cells were resuspended in FB. All samples were
acquired on a FACSCalibur with CellQuest software (both BD
Biosciences) and analyzed using the FlowJo software (Tree Star Inc.).
Determination of virus titers
Blood samples were obtained from LCMV-infected mice at
indicated times, diluted 5-fold in MEM (5% FCS) containing 50 U.I.
of Liquemin (Drossapharm) and frozen. Organs were collected in 1 ml
MEM (5% FCS) and smashed with a Tissue Lyser (Qiagen). Samples
were stored at 280uC until further analysis by plaque forming assay
[75].
Treg cell suppression assay
Responder CD4+ T cells were purified from naı¨ve spleens by
positive MACS separation (Miltenyi Biotec) and labeled with 25 mM
CFSE (Molecular Probes, C-1157) at a density of 106 cells/ml in PBS
containing 0.5% BSA for 7 min at RT. The labeling reaction was
stopped with pure FCS and cells were washed twice with IMDM
containing 10% FCS. As suppressor cells, CD25+ Treg cells were
FACS-sorted from MACS-purified CD4+ T cells isolated from
LCMV-DOC infected DEREG and IL-21R2/2 DEREG mice.
CFSE-labeled responder CD4+ T cells (16105/well) and sorted Treg
cells were then incubated at defined responder/suppressor ratios (1:1,
2:1, 4:1) in RPMI (10% FCS, 50 mM b-ME and 100 U/ml IL-2) for 6
days in the presence of 56106 anti-CD3/CD28-coated (both
eBioscience) latex beads.
Hydrodynamic gene delivery
Mouse IL-21 coding sequence was amplified by PCR and linked
with hIgG1 Fc domain and cloned into pLIVE in vivo expression
vector (Mirus Bio). Endotoxin-free plasmid DNA (100 mg) was
injected i.v. in PBS in a volume equal to 10% body weight
(0.1 ml/g) within 5 s. As a control, a hIgG1 expression vector was
injected. To supplement IL21, mice received i.p. injections of 2 mg
recombinant IL-21-hIgG1 fusion protein (kindly provided by
Daniel Christ, Garvan Institute for Medical Research, Sydney,
Australia) or PBS two times daily.
Statistical analysis
Data are shown as average 6SEM. Statistical analysis was
performed with the unpaired two-tailed t–test (except for Fig. 1B–
E) using the Prism 4.0 software (GraphPad Software). Differences
were considered significant for p,0.05 and were denoted as *,
p,0.05; **, p,0.01; ***, p,0.001.
Supporting Information
Figure S1 Expansion of Treg cells with IL-2ic. Mice were
treated with IL-2ic as depicted in (A). (B) Treg cell populations in
blood, spleens, and livers of treated as compared to untreated (ctrl)
mice. Shown are dot plots of representative individuals of groups
(n = 4). Percentages and total cell counts of Foxp3 cells are
indicated in quadrants.
(EPS)
Figure S2 Expanded Treg cell population impairs the
antiviral T cell response and promotes virus persis-
tence. (A–C) Kinetics of CD8+ and CD4+ T cells during infection
with 2000 PFU LCMV-DOC in presence or absence of IL-2ic-
mediated Treg cell expansion. Shown are percentages and
activation status of (A) CD8+ T cells, (B) gp33-specific CD8+ T
cells and (C) Foxp3-negative CD4+ T cells in blood. Lym,
lymphocytes. Lines indicate averages of groups. Data are
representative of two independent experiments (n = 4/group).
(EPS)
Figure S3 Treg cells promote virus persistence in a
model of acute viral infection. (A) Percentages of gp33-
specific CD8+ T cells in blood, spleens and livers of mice infected
with 200 PFU LCMV-WE in the presence or absence of IL-2ic-
mediated Treg cell expansion. (B, C) Percentage of IFN-c- and
TNF-a-producing virus-specific CD8+ and CD4+ T cells at (B) 15
and (C) 29 dpi as assessed by intracellular cytokine staining after
restimulation with gp33 or gp61 peptide, respectively. Dot plots
show representative mice and bar graphs indicate means 6SEM
of groups (n = 3–4) of mice. (D) Virus titers in blood and organs of
individual mice as determined by plaque forming assay 15 dpi.
Dotted lines indicate the detection limit (DTL). Data are
representative of two independent experiments.
(EPS)
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